Appointment of Marc Le Bozec as Interim CEO

Core Points - OSE Immunotherapeutics has appointed Marc Le Bozec as interim CEO following the termination of Nicolas Poirier's position [2][3] - The Board of Directors is conducting a formal search for a new permanent CEO while empowering Le Bozec to lead a strategic evaluation of the company's business [3][5] - Nicolas Poirier will continue as Chief Scientific Officer, and no compensation will be paid for his termination as CEO [4] Company Strategy - The focus of the strategic evaluation will be on maximizing value across partnerships, finances, and clinical development programs [3] - The Board aims to realign the company's strategy and accelerate progress during this transition [5] - Marc Le Bozec emphasized the importance of reassuring teams and maintaining a focus on therapeutic innovation [6] Leadership Background - Marc Le Bozec has extensive experience in the biotech sector, having created and managed two biotech investment funds and previously served as CFO of Cellectis [7][8] - His background includes raising €120 million for Cellectis and preparing the company for its Nasdaq listing [8] - Le Bozec's career began in organizational and strategy consulting before founding his first biotech company in 1998 [9] Company Overview - OSE Immunotherapeutics is dedicated to developing first-in-class assets in immuno-oncology and immuno-inflammation [10] - The company collaborates with leading academic institutions and biopharmaceutical companies to bring transformative medicines to market [10]